Glenmark launches Ryaltris®-AZ at an affordable price in India
Chennai , 4th May 2021 : Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company,announced the launch of Ryaltris -AZ Nasal Spray for the treatment of moderate to severe allergic rhin itis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country.
Glenmark is the first company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasonefuroate50 mcg + Azelastine 140 mcg.
According to a study, around 20-30 % of the Indian population suffers from allergic rhini tis. Moreover, in India, patients have to bear the drug cost on their own and so the price of the drug becomes a major factor that impac ts treatment adherence. While the avera ge cost of therapy of top 10 existing brands of thesimilar drug category is Rs. 365, Glen mark’s Ryaltris -AZ nasal spray has been launched at a breakthrough price of Rs. 175/- per pack of 75 metered doses (MD). This cost is around 52% less as compared to the average price of the top 10 brands of the similar drug category in the market.
Ryaltris -AZ nasal spray, developed by Glenmark , is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
Allergic rhinitis is a chronic upper respiratory disease estimated to affect around 10 to 40% of the population worldwide. Indeed, allergic rhinitis contributes to missed or unproductive time at work, sleep problems anddecr eased involvement in outdoor activities. Being a topical therapy Ryaltris -AZ offers many advantages over oral therapies, such as delivering greater concentrations of drug to the receptor sites at the source of the allergic inflammation andreduced risk of systemic side effects.
